Nevro Corp. (NVRO) Research

Nevro Corp. is a medical technology firm that delivers solutions for individuals experiencing persistent pain, serving markets both domestically in the United States and across the globe. The company's core business involves the development and market introduction of the Senza spinal cord stimulation (SCS) system, an advanced, clinically supported neuromodulation platform specifically engineered to alleviate chronic pain. This portfolio encompasses its newer generations, the Senza II and Senza Omnia systems. Additionally, Nevro offers its proprietary 10 kHz Therapy, providing neuromodulation approaches grounded in robust clinical evidence for effective chronic pain management. Its products are distributed through a diverse strategy, utilizing a dedicated direct sales team complemented by a network of specialized sales agents and independent distributors. Founded in 2006, Nevro Corp. maintains its corporate headquarters in Redwood City, California.

Market snapshot

Symbol
NVRO
Price
$5.84
Day change
0.00%
Market cap
$224.1M
P/E ratio
-1.91x
52-week range
3.165-13.3
Sector
Healthcare
Industry
Medical - Devices
Analyst price target
$30.32

Peer companies

  • BioSig Technologies, Inc. (BSGM)
  • CARGO Therapeutics, Inc. Common Stock (CRGX)
  • Second Sight Medical Products Inc (EYESW)
  • Inozyme Pharma, Inc. (INZY)
  • LakeShore Biopharma Co., Ltd (LSB)
  • Shineco, Inc. (SISI)
  • Acelyrin, Inc. (SLRN)
  • Sonida Senior Living, Inc. (SNDA)

Recent insider activity

  • GROSSMAN D KEITH — D-Return (228552 shares) on 2025-04-03
  • Kosaraju Sridhar — D-Return (46575 shares) on 2025-04-03
  • mcCormick Shawn — D-Return (46035 shares) on 2025-04-03
  • SIEGEL SUSAN E — D-Return (7382 shares) on 2025-04-03
  • Karros Kirt P — D-Return (17452 shares) on 2025-04-03

Open Nevro Corp. (NVRO) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.